Ann: AstraZeneca to use new ResApp software in clinical study, page-70

discerning, I'm bullish on RAP, therefore who cares what I think. AZ thinks its worthy/validated, obviously in-house examined. Why "obviously," because AZ have tied themseves, a great part of their reputation (think cachet, credibility in science, respect and their SP(!)). So, I'll defer to that. I think of this as AZ did my due diligence on the sciency bit.

RAP is Risk. This news De-risks RAP. The current RAP risk, though, is to the UPside.

On a scale of personal risk: buy nothing to buy a partial position, to incrementally buy more, to go All In.

OV